Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 3 | 2018 | 293 | 1.460 |
Why?
|
| Burkitt Lymphoma | 3 | 2024 | 146 | 1.040 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 239 | 1.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1250 | 0.880 |
Why?
|
| Mucositis | 1 | 2022 | 18 | 0.830 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 162 | 0.740 |
Why?
|
| Sarcoma, Kaposi | 4 | 2023 | 120 | 0.720 |
Why?
|
| Malnutrition | 1 | 2022 | 196 | 0.660 |
Why?
|
| Positron-Emission Tomography | 2 | 2017 | 285 | 0.630 |
Why?
|
| Malawi | 9 | 2024 | 389 | 0.550 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 300 | 0.550 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 158 | 0.540 |
Why?
|
| Neoplasms | 4 | 2023 | 2753 | 0.500 |
Why?
|
| Preoperative Care | 1 | 2017 | 350 | 0.490 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 49 | 0.390 |
Why?
|
| Child | 18 | 2024 | 24064 | 0.370 |
Why?
|
| Vincristine | 2 | 2020 | 208 | 0.310 |
Why?
|
| HIV Infections | 4 | 2023 | 1858 | 0.290 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 422 | 0.280 |
Why?
|
| Legal Guardians | 1 | 2024 | 13 | 0.240 |
Why?
|
| Africa South of the Sahara | 2 | 2023 | 112 | 0.230 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 5013 | 0.210 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.210 |
Why?
|
| Malaria, Falciparum | 1 | 2022 | 44 | 0.200 |
Why?
|
| Quality of Life | 2 | 2022 | 1913 | 0.200 |
Why?
|
| Malaria | 1 | 2022 | 81 | 0.200 |
Why?
|
| Wilms Tumor | 1 | 2023 | 112 | 0.190 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2022 | 18 | 0.190 |
Why?
|
| Hematology | 1 | 2022 | 36 | 0.190 |
Why?
|
| Humans | 19 | 2024 | 122296 | 0.190 |
Why?
|
| Retrospective Studies | 6 | 2023 | 15853 | 0.180 |
Why?
|
| Child, Preschool | 6 | 2024 | 13777 | 0.180 |
Why?
|
| Creatinine | 1 | 2022 | 379 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 408 | 0.180 |
Why?
|
| Terminal Care | 1 | 2022 | 114 | 0.180 |
Why?
|
| Methotrexate | 1 | 2022 | 341 | 0.180 |
Why?
|
| Male | 12 | 2024 | 59522 | 0.180 |
Why?
|
| Nutritional Status | 1 | 2022 | 297 | 0.180 |
Why?
|
| Adolescent | 8 | 2024 | 18940 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 223 | 0.170 |
Why?
|
| Female | 12 | 2024 | 64883 | 0.170 |
Why?
|
| Anemia | 1 | 2023 | 338 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 815 | 0.160 |
Why?
|
| Vinblastine | 1 | 2018 | 46 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 426 | 0.160 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 333 | 0.150 |
Why?
|
| Prednisolone | 1 | 2018 | 73 | 0.150 |
Why?
|
| Etoposide | 1 | 2018 | 119 | 0.150 |
Why?
|
| Dacarbazine | 1 | 2018 | 85 | 0.150 |
Why?
|
| Lymphoma | 1 | 2021 | 323 | 0.150 |
Why?
|
| Bleomycin | 1 | 2018 | 150 | 0.150 |
Why?
|
| Podophyllotoxin | 1 | 2017 | 7 | 0.150 |
Why?
|
| Carmustine | 1 | 2017 | 26 | 0.150 |
Why?
|
| Autografts | 1 | 2017 | 26 | 0.150 |
Why?
|
| Melphalan | 1 | 2017 | 49 | 0.140 |
Why?
|
| Cytarabine | 1 | 2017 | 99 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2018 | 307 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 872 | 0.120 |
Why?
|
| Infant | 4 | 2023 | 12302 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 360 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.120 |
Why?
|
| Cytokines | 1 | 2019 | 1272 | 0.110 |
Why?
|
| Prognosis | 2 | 2024 | 4488 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 1102 | 0.100 |
Why?
|
| Survival Rate | 1 | 2017 | 1997 | 0.100 |
Why?
|
| Adult | 4 | 2024 | 28733 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3301 | 0.060 |
Why?
|
| Risk Factors | 1 | 2018 | 9902 | 0.060 |
Why?
|
| Tanzania | 1 | 2023 | 66 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2023 | 172 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2024 | 513 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 182 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 170 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 603 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2022 | 213 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 126 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 162 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 30 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 581 | 0.040 |
Why?
|
| Decision Making | 1 | 2024 | 650 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 397 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1247 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 450 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1227 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 663 | 0.040 |
Why?
|
| Palliative Care | 1 | 2022 | 424 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 738 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2019 | 394 | 0.040 |
Why?
|
| Prevalence | 1 | 2022 | 2371 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 978 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 5963 | 0.020 |
Why?
|
| United States | 1 | 2023 | 10487 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 8760 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8096 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 25640 | 0.020 |
Why?
|